This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England.
One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
Hae Jung, Beyhan Ataseven, Mark Verrill, Xavier Pivot, Michelino De
Laurentiis, Nedal Al-Sakaff, Sabine Lauer, Mona Shing, Joseph Gligorov,
Hamdy A. Azim
article reports results of the SafeHer subgroup analysis, which
assessed the safety of fixed-dose subcutaneous trastuzumab as an
adjuvant therapy in HER2-positive early breast cancer by body weight.
novel quantitative index to represent the heterogenetic characteristics
of metastatic disease is proposed, and the value of heterogeneity among
metastatic lesions on pretreatment PET/CT in predicting treatment
outcome of patients with mTNBC is evaluated.
article provides context for the value and risks of adjuvant
anthracyclines, focusing on recently reported evidence of disease and
patient characteristics that influences decision making regarding the
use of adjuvant anthracyclines.
article reports the incidence of new-onset thyroid function test
abnormalities in patients undergoing treatment with ipilimumab,
nivolumab, pembrolizumab, and combined therapy with ipilimumab and
nivolumab and describes the clinical course of these patients.
Benjamin A. Weinberg, Joanne Xiu, Jimmy J. Hwang, Anthony F. Shields, Mohamed E. Salem, John L. Marshall
PD-L1 is an important predictive biomarker for response to immune
checkpoint inhibition in gastric and gastroesophageal junction
adenocarcinoma, high microsatellite instability (MSI), mismatch repair
deficient, and high tumor mutational load (TML) have a potential role as
positive predictive biomarkers for immune checkpoint inhibition in
other tumor types. This study aimed to identify more patients with
gastric and gastroesophageal junction adenocarcinoma that have these
positive biomarkers and to delineate the overlap between PD-L1, MSI, and
Cremolini, Daniele Rossini, Erika Martinelli, Filippo Pietrantonio,
Sara Lonardi, Silvia Noventa, Emiliano Tamburini, Giovanni Luca
Frassineti, Stefania Mosconi, Federico Nichetti, Sabina Murgioni, Teresa
Troiani, Beatrice Borelli, Gemma Zucchelli, Alessandro Dal Maso,
Vincenzo Sforza, Gianluca Masi, Carlotta Antoniotti, Maria Di
Bartolomeo, Rosalba Miceli, Fortunato Ciardiello, Alfredo Falcone
new fluoropyrimidine recently entered the scene of metastatic
colorectal cancer (mCRC): trifluridine/tipiracil, also known as TAS-102.
Improving the cost/efficacy ratio of TAS-102 in mCRC is needed to avoid
toxicities in a definitely palliative setting. ECOG performance score,
LDH levels, and time from diagnosis of metastatic disease may help
identify patients most likely to benefit. Properly designed prognostic
tools, such as the "ColonLife" nomogram, may allow for better treatment
decisions for patients with limited life expectancy.
Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian, Karol Sikora
article reviews the evolution of the global biosimilar landscape and
provides examples of current discrepancies among biosimilar regulatory
frameworks in different regions. In addition, efforts to address
regulatory inconsistencies are reviewed, and the importance of
healthcare professional and patient education in acceptance of
biosimilars is highlighted.
Hala T. Borno, Li Zhang, Adam Siegel, Emily Chang, Charles J. Ryan
barriers to clinical trial participation exist; however, the burden of
cost and time associated with travel to visits may contribute to
disparities in care. This analysis may inform ways that health care
payers and systems can reduce the burden to encourage equitable
recruitment and retention in cancer clinical trials.
Manmeet S. Ahluwalia, Kevin Becker, Benjamin P. Levy
review article discusses preclinical and clinical evidence for EGFR
tyrosine kinase inhibitors in the treatment of central nervous system
metastases, within the context of current treatment options.
Younger, Saskia Litière, Axel Le Cesne, Olivier Mir, Hans Gelderblom,
Antoine Italiano, Sandrine Marreaud, Robin Lewis Jones, Alessandro
Gronchi, Winette T.A. van der Graaf
the large number of elderly patients with cancer, they are often
disproportionally underrepresented in clinical research trials. This
article reports outcomes of elderly patients treated with first-line
chemotherapy within EORTC-STBSG clinical trials.
accurate understanding of a diagnosis is important for patients with
advanced cancer so that the patient can make decisions that align with
preferences and values. This study examined the understanding of
prognosis and therapy goals in patients with newly diagnosed advanced
lung cancer, as well as the understanding of the patients' caregivers.
David Hui, Kelly Kilgore, Minjeong Park, Diane Liu, Yu Jung Kim, Ji Chan Park, Frank Fossella, Eduardo Bruera
better understanding of clinician and patient characteristics that are
associated with referral for palliative care in a real-world context may
help to overcome barriers to timely palliative care access. This
article reports patterns of outpatient palliative care referral among
thoracic medical oncologists and identifies oncologist characteristics
associated with greater referral.
treatment strategies for platinum‐resistant recurrent ovarian cancer
are needed. Programmed cell death‐1 (PD‐1) signaling is a new target of
antitumor therapy that involves immune reactivation; however, its
antitumor effect on subsequent chemotherapy is unclear. Two
representative cases are described here.
this Letter to the Editor, Franses and Ting respond to questions about
their recently published article on improved detection of circulating
epithelial cells in patients with intraductal papillary mucinous
pemphigoid is an autoimmune subepidermal blistering disease
characterized by the development of tense bullae and is most frequently
seen in the elderly. PD-1/PD-L1-induced bullous pemphigoid (BP) has
emerged as a potentially serious dermatologic toxicity. This article
reports a case of a 72-year-old woman who developed BP shortly after
initiating treatment with the PD-1 inhibitor nivolumab for metastatic
non-small cell lung cancer.